Caribou Biosciences Holds Near $2 With June Cancer Drug Updates Ahead
Caribou Biosciences shares rose about 1% to $2.01 on Friday ahead of cancer drug data updates expected in June. The company plans to present new results on vispa-cel and CB-011 at the European Hematology Association meeting. Caribou had $118.6 million in cash at March 31 and raised $2.3 million by selling 1.08 million shares in the first quarter. The stock traded before a three-day U.S. market holiday.